Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
BeOne Medicines
BeOne Medicines
BeOne Medicines
Nurix Therapeutics, Inc.
Verismo Therapeutics
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
AbbVie
Massachusetts General Hospital
Nurix Therapeutics, Inc.
Beth Israel Deaconess Medical Center
ModeX Therapeutics, An OPKO Health Company
Newave Pharmaceutical Inc
Schrödinger, Inc.
BeOne Medicines
Carna Biosciences, Inc.
Dana-Farber Cancer Institute
University of Ulm
Memorial Sloan Kettering Cancer Center
Mayo Clinic
Accutar Biotechnology Inc
Northwell Health
Centre Hospitalier Universitaire, Amiens
Stanford University
Barbara Ann Karmanos Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Centre Hospitalier Universitaire, Amiens
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
University College, London
Kosin University Gospel Hospital